[
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day",
    "summary": "Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day",
    "url": "https://finnhub.io/api/news?id=6e093d1e81701fc26eb860cc4d9551d7f50ced34ddc9f94342b57c22d452ff84",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740588060,
      "headline": "Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day",
      "id": 132886653,
      "image": "",
      "related": "REGN",
      "source": "MarketWatch",
      "summary": "Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day",
      "url": "https://finnhub.io/api/news?id=6e093d1e81701fc26eb860cc4d9551d7f50ced34ddc9f94342b57c22d452ff84"
    }
  },
  {
    "ts": null,
    "headline": "Odronextamab BLA Accepted for FDA Review for the Treatment of Relapsed/Refractory Follicular Lymphoma",
    "summary": "FDA decision expected by July 30, 2025TARRYTOWN, N.Y., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the Biologics License Application (BLA) for odronextamab in relapsed/refractory (R/R) follicular lymphoma (FL) after two or more lines of systemic therapy. The target action date for the FDA decision is July 30, 2025. Acceptance of the BLA resubmission fo",
    "url": "https://finnhub.io/api/news?id=b29b7278b385c0491d899661f96bcf456606f82362354fe0e60941dfe8b46923",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740571200,
      "headline": "Odronextamab BLA Accepted for FDA Review for the Treatment of Relapsed/Refractory Follicular Lymphoma",
      "id": 133186701,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "FDA decision expected by July 30, 2025TARRYTOWN, N.Y., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the Biologics License Application (BLA) for odronextamab in relapsed/refractory (R/R) follicular lymphoma (FL) after two or more lines of systemic therapy. The target action date for the FDA decision is July 30, 2025. Acceptance of the BLA resubmission fo",
      "url": "https://finnhub.io/api/news?id=b29b7278b385c0491d899661f96bcf456606f82362354fe0e60941dfe8b46923"
    }
  },
  {
    "ts": null,
    "headline": "Merck's Oncology Strength: Beating Wall Street Again",
    "summary": "Merck's Q4 2024 results surpassed expectations, driven by strong oncology sales and growth in Keytruda. See why I think MRK may work for income investors.",
    "url": "https://finnhub.io/api/news?id=48cc045b6210dbf5fc551d979a18cc216581d878f6df5c6d273d0c4b6879a62b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740561344,
      "headline": "Merck's Oncology Strength: Beating Wall Street Again",
      "id": 132878313,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/151810706/image_151810706.jpg?io=getty-c-w1536",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "Merck's Q4 2024 results surpassed expectations, driven by strong oncology sales and growth in Keytruda. See why I think MRK may work for income investors.",
      "url": "https://finnhub.io/api/news?id=48cc045b6210dbf5fc551d979a18cc216581d878f6df5c6d273d0c4b6879a62b"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron : FDA Accepts Odronextamab Lymphoma Drug Resubmission",
    "summary": "By Colin Kellaher Regeneron Pharmaceuticals said the Food and Drug Administration has accepted for review its resubmitted application seeking approval of odronextamab for certain patients with...",
    "url": "https://finnhub.io/api/news?id=f6fa92c079f2f75f6414bf7ca2b412b40c3927638cf660689e0f087c4fc06c4d",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740556753,
      "headline": "Regeneron : FDA Accepts Odronextamab Lymphoma Drug Resubmission",
      "id": 132877816,
      "image": "",
      "related": "REGN",
      "source": "Finnhub",
      "summary": "By Colin Kellaher Regeneron Pharmaceuticals said the Food and Drug Administration has accepted for review its resubmitted application seeking approval of odronextamab for certain patients with...",
      "url": "https://finnhub.io/api/news?id=f6fa92c079f2f75f6414bf7ca2b412b40c3927638cf660689e0f087c4fc06c4d"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron: FDA Accepts Odronextamab Lymphoma Drug Resubmission",
    "summary": "Regeneron: FDA Accepts Odronextamab Lymphoma Drug Resubmission",
    "url": "https://finnhub.io/api/news?id=fb15811bf46f960ea95a122b3b432d791f4339a82d03a973b2c112d690d2a6dc",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740555780,
      "headline": "Regeneron: FDA Accepts Odronextamab Lymphoma Drug Resubmission",
      "id": 132886654,
      "image": "",
      "related": "REGN",
      "source": "MarketWatch",
      "summary": "Regeneron: FDA Accepts Odronextamab Lymphoma Drug Resubmission",
      "url": "https://finnhub.io/api/news?id=fb15811bf46f960ea95a122b3b432d791f4339a82d03a973b2c112d690d2a6dc"
    }
  },
  {
    "ts": null,
    "headline": "Anti-Kickback Statute Premised False Claims Cases: The \"But For\" Causation Standard Finds Support From First Circuit",
    "summary": "It's now 3-1, with the First Circuit aligning with the Sixth and Eighth Circuits finding the meaning of the words resulting from — as used in a 2010 amendment to the federal Anti-Kickback Statute...",
    "url": "https://finnhub.io/api/news?id=e717d30805babe93b6abb6f3ab3379f6f75be69dda50c6cec2775ab2b500c161",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740539286,
      "headline": "Anti-Kickback Statute Premised False Claims Cases: The \"But For\" Causation Standard Finds Support From First Circuit",
      "id": 132876165,
      "image": "",
      "related": "REGN",
      "source": "Finnhub",
      "summary": "It's now 3-1, with the First Circuit aligning with the Sixth and Eighth Circuits finding the meaning of the words resulting from — as used in a 2010 amendment to the federal Anti-Kickback Statute...",
      "url": "https://finnhub.io/api/news?id=e717d30805babe93b6abb6f3ab3379f6f75be69dda50c6cec2775ab2b500c161"
    }
  }
]